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Abstract: Secondary sclerosing cholangitis in critically ill patients
(SSC-CIP) is an important differential diagnosis in patients presenting
with cholestasis and PSC-like cholangiographic changes in endoscopic
retrograde cholangiography (ERC). As a relatively newly described
entity, SSC-CIP is still underdiagnosed, and the diagnosis is often
delayed. The present study aims to improve the early detection of
SSC-CIP and the identification of its complications.
A total of 2633 records of patients who underwent or were listed for
orthotopic liver transplantation at the University Hospital Charite´, Berlin,
were analyzed retrospectively.Theclinicalpresentationandoutcome(mean
follow-up 62.7 months) of the 16 identified SSC-CIP cases were reviewed.
Cholestasis was the first sign of SSC-CIP. GGT was the predominant
enzyme of cholestasis. Hypercholesterolemia occurred in at least 75% of
the patients. SSC-CIP provoked a profound weight loss (mean 18kg) in
94% of our patients. SSC-CIPwas diagnosed by ERC in all patients. The 3
different cholangiographic features detected correspond roughly to the
following stages: (I) evidence of biliary casts, (II) progressive destruction, Andreas Adler, M ott, MD, PhD,
haus, MD, PhD, and Daniel Seehofer, MD, PhD
cholangiosepsis, cholangitic liver abscesses, acalculous cholecystitis, or
gallbladder perforation. SSC-CIP was associated with worse prognosis;
transplant-free survival was 40 months (mean).
Because of its high rate of serious complications and unfavorable
prognosis, it is imperative to diagnose SSC-CIP early and to differentiate
SSC-CIP fromother types of sclerosing cholangitis. Specific characteristics
enable identification of SSC-CIP. Early cooperation with a transplant
center and special attention to biliary complications are required after
diagnosis of SSC-CIP.
(Medicine 94(49):e2188)
Abbreviations: AAC = acute acalculous cholecystitis, ALP =
alkaline phosphatase, ALT = alanine aminotransferase, ASAT =
aspartate aminotransferase, CK = creatinine kinase, COPD =
chronic obstructive pulmonary disease, ERC = endoscopic
retrograde cholangiography, GGT = gamma-glutamyl
transpeptidase, ICU = intensive care unit , IgG4 =
Immunoglobulin G4, mg/dL = milligrams per deciliter, OLT =
orthotopic liver transplantation, PBC = primary biliary cirrhosis,
PSC = primary sclerosing cholangitis, SDM = standard deviation of
the mean, SSC = secondary sclerosing cholangitis, SSC-CIP =
secondary sclerosing cholangitis in critically ill patients, TNF-a =
tumor necrosis factor alpha, U/L = units per liter.
INTRODUCTION
T he diversity of sclerosing cholangiopathies seems greaterthan believed 30 years ago. The differential diagnosis
includes, for example, IgG4-related sclerosing cholangitis,
AIDS-relatedcholangiopathy, ischemiccholangiopathy, eosinophi-
lic cholangitis, and primary sclerosing cholangitis (PSC). In recent
years, there havebeen increasing numbers of reports on anewentity
of sclerosing cholangiopathy. This type of secondary sclerosing
cholangitis occurs in association with intensive-care treatment of
patients with major surgery, trauma, burns, and other life-threaten-
ing events. Secondary sclerosing cholangitis in critically ill patients
(SSC-CIP) is most likely caused by severe arterial hypotension/
shock.1–5 SSC-CIP is a progressive cholestatic liver disease charac-
terized by necrosis of the bile duct epithelium, which leads to the
rapid destruction of the visible intrahepatic bile ducts. The disease
runs a chronic, irreversible course and can only be cured by liver
transplantation. Here, we report our experience with 16 SSC-CIP
cases. The aim of our study was to define the characteristic clinical
features of SSC-CIP.IALS AND METHODS
linical data on critically ill patients who
sclerosing cholangitis. All cases were
www.md-journal.com | 1
was censored. The study was approved by the local Ethics
tendency to affect men more often than women (11 men to 5






Severe postoperative bleeding after gynaecologic surgery 1
Subarachnoid haemorrhage 1
Respiratory insufficiency due to acute exacerbation of COPD 2
Total number of cases 16
Gender (male/female) 11/5
Male: female 2.2
Mean age at diagnosis (yearsSDM) 45.87 14.64
Median age at diagnosis (years, range) 48 (18–63)
Mean follow-up (monthsSDM) 62.7 32
Median follow-up (months, range) 62 (5.6–171)
Duration of intensive care treatment
Mean (daysSDM) 38.75 23.87
Median (days, range) 31 (9–82)
Outcome; survival free of LTx and survival after LTx
Mean time interval—onset of cholestasis to listing for LTx (daysSDM) 322 257
Median time interval—onset of cholestasis to listing for LTx (days, range) 225 (78–1004)
Mean time interval—onset of cholestasis to LTx (daysSDM) 1075 545
Median time interval—onset of cholestasis to LTx (days, range) 1271 (189–1718)
Mean survival free of LTx (days) 1223 741
Median survival free of LTx (days, range) 1336 (189–2472)
Mean survival after LTx (days) 1187 1051
Median survival after LTx (days, range) 1075 (14–2658)
COPD¼ chronic obstructive pulmonary disease, LTx¼ liver transplantation, SDM¼ standard deviation of the mean, SSC-CIP¼ secondary
Leonhardt et al Medicine  Volume 94, Number 49, December 2015recruited retrospectively by reviewing the hospital records of
patients who received (2473) or were listed for orthotopic liver
transplantation (OLT) at the Charite´ University Hospital Berlin
between January 1990 and May 18, 2011. Sixteen patients with
a confirmed diagnosis of SSC-CIP were identified. The Charite´
Department of Transplantation Surgery is a tertiary care center
and most cases with SSC-CIP were referred from other hospi-
tals. Therefore, in most patients, the initial treatment—especi-
ally intensive care treatment—was performed in outside
hospitals. After listing for OLT, endoscopic management of
the patients was performed at the Endoscopy Unit of Depart-
ment of Gastroenterology and Hepatology/Charite´, a high-
volume center for biliary endoscopy. All patients had survived
a prior acute life-threatening event followed by intensive care
treatment. The reasons for admission to the intensive care unit
(ICU) are shown in Table 1. Before admission to ICU, no patient
had evidence of liver or bile duct disease and had unremarkable
liver function tests. Clinical information about each patient was
obtained by review of the medical records. Detailed pieces of
information regarding the clinical course, laboratory
parameters, ultrasound and endoscopic retrograde cholangio-
graphy (ERC) findings were collected. The diagnosis of SSC-
CIP was established by ERC (16/16) and confirmed by liver
histology (12/16 patients). The median follow-up was 62
months (range: 5.6–171). The onset of cholestasis was defined
as an increase in the cholestatic parameters (gamma-glutamyl-
sclerosing cholangitis in critically ill patients.transferase [GGT], alkaline phosphatase [ALP], and bilirubin)
to more than twice the upper limit of normal. Data were
summarized as mean and standard deviation of the mean or
2 | www.md-journal.comwere presented as medians with ranges or percentages. We
tested for gender differences using the 2-sided binomial prob-
ability test. Cholesterol elevation was tested for significance
with the 2-sided 1-sample t test. P values of <0.05 were
regarded as statistically significant. Statistical analyses were
performed using Stata software, version 13.1 (Stata Corp).
Transplant-free survival curves were calculated by the
Kaplan–Meier method. The starting point for survival analysis
was defined as the time of onset of cholestasis. Either liver
transplantation or death from liver disease was counted as an
event, whereas ‘‘patients alive without liver transplantation’’Committee of the Charite´, and all surviving patients gave their
written informed consent to having their data recorded.
RESULTS
At time of diagnosis, the patients had a mean age of
46 14.6 years. All patients required intensive care treatment
for a mean 39 23.9 days (Table 1). The disease showed awomen, ratio of 2.2), but the difference was not significant
(P¼ 0.210, 2-sided binominal probability test).
Liver Function Tests and Other Laboratory
Parameters
The onset of cholestasis was seen 7 days (median) after the
initial life-threatening event. Gamma-glutamyl-transferase
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
the second bifurcation of the intrahepatic bile ducts. The destruc-
Medicine  Volume 94, Number 49, December 2015(GGT) was the first parameter to become elevated, and alkaline
phosphatase (ALP) followed within a few days. Hyperbiliru-
binemia could be observed after a mean of 15.5 10 days
(median: 13 days) and was therefore the last sign of disease
detected. This characteristic sequence of GGT, ALP, and
bilirubin elevation was observed in 13/16 patients (Fig. 1).
Cholestasis reached a peak after 31 14 days (range: 14–68
days). GGT levels peaked at 20 to 50 times the upper limit of
normal, whereas the elevation of AP levels was less pronounced
(5 to no more than 21 times upper limit of normal). Serum
alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) levels were moderately elevated (mean:
281.9 212.9U/L for AST, and 271.4 165.7U/L for ALT).
Initial cholestasis was accompanied by transient creatinine
elevation in half (8/16) of the patients. Data on cholesterol
levels were available in 12 patients, all developed marked
hypercholesterolemia (mean 535.6 243.9mg/dL; median
476.5) within the first year of disease (Table 2). Compared
to the normal value of 200mg/dL, the cholesterol value
observed in our population was significantly elevated
(P¼ 0.001). In transplanted patients, hypercholesterolemia
resolved after OLT.
Diagnostic Studies
Ultrasound: For differential diagnosis of the cholestasis,
ultrasound scans were performed in all 16 patients, starting 10.5
days (¼median; mean 29.31 60.05 days; range 1–247 days)
after the onset of cholestasis. Dilatation of the extrahepatic bile
duct was observed in 31% (5/16) of the patients. Isolated intra-
hepatic cholestasis was detected in another 2 patients, bringing
the total number of cases with biliary system abnormalities to 7/
FIGURE 1. Course of cholestasis with typical sequence of GGT, ALP,
and bilirubin; here, in a patient of our series with polytrauma.
ALP¼ alkaline phosphatise, GGT¼gamma-glutamyl transpeptidase.16. Furthermore, sonographic signs of cholecystitis were
observed in 8/16patients.A total of 88%of the patients developed
sonographic signs of liver cirrhosis within 6 months (mean).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Endoscopic retrograde cholangiography (ERC): In all
patients, the diagnosis of SSC-CIP was based on typical chol-
angiographic findings. The mean delay from first biochemical
signs of cholestasis until the time of diagnosis was 85.7 80.7
days (range: 13–271 days, median: 54 days). Totally 81% of the
patients had only intrahepatic involvement, whereas 19% had
evidence of intra- and extrahepatic bile duct involvement.
However the extrahepatic ductal changes were minor. Three
different cholangiographic features (I-III) of SSC-CIP were
identified (Fig. 2).
I. Early Stage: Biliary Cast Formation
The early stage of disease was characterized by the pre-
sence of multiple ribbon-like intraductal filling defects in the
biliary tract. These filling defects were consistent with biliary
casts and were found in 87% (14/16) of our patients in the first
year after the initial injury. The shortest and longest time until
detection was 13 and 265 days after the onset of cholestasis. In 3
patients, no signs of biliary cast formation were detected during
the first ERC session but were observed later on the third or
fourth ERC session. In 7/14 patients, biliary casts were found in
multiple consecutive ERC sessions.
II. Intermediate Stage: Progressive Destruction
of the Intrahepatic Bile Ducts
The further course of the disease was characterized by
rapidly progressive intrahepatic bile duct destruction beyond
Natural History of SSC-CIPtion of the intrahepatic bile ducts due to epithelial necrosis
manifests at ERC as contour defects and irregular wall contours.
III. Late Stage: Obliteration of the Intrahepatic
Bile Ducts/Picture of Pruned Tree
As a result of the progressive destruction, the intrahepatic
bile duct branches were eventually obliterated, leaving only a
rudimentary central biliary system (see also Fig. 3). In ERC,
contrast enhancement of the bile ducts occurred only below the
second bifurcation. In the later stage, the picture was that of a
pruned tree. At least one side of the biliary system was
obliterated, but mostly both sides were affected. The median
time to the appearance of this constellation was 86.5 days after
the onset of cholestasis (mean: 133 127 days).
Liver histology: Liver histology data were available in 11/
16 cases, either by liver biopsy, autopsy, or by histological
findings from the explanted liver. The liver biopsy specimens
were obtained 22 to 351 days after the onset of cholestasis
(mean: 133 124 days, median: 102 days). All biopsy speci-
mens showed histopathological changes, which were located
mainly in the portal tracts. Abnormalities such as portal tract
dilatation, ductular reaction, and portal tract infiltration were
described. Fibrosis of portal tracts was detected in 5 of 6 liver
biopsies. Cirrhosis was found in 7/9 of the explanted livers and
portal fibrosis was detected in 2/9 patients with early trans-
plantation on day 189 and 237 (Table 2). In the explanted livers,
the histological evidence of necrosis of the larger bile ducts in
the hilar region is particularly worth mentioning (Supplement 1,
http://links.lww.com/MD/A550).
Weight Loss
Severe weight loss (mean: 18 11 kg; median: 18.5 kg)
occurred in the first year after the initial injury in 15/16 patients.
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Medicine  Volume 94, Number 49, December 2015 Natural History of SSC-CIPFIGURE 2. Cholangiographic findings of SCC-CIP. SSC-CIP¼ secoICU stay and occurred, in some cases, despite a short period of
intensive care treatment (Table 2).Complications of SSC-CIP
Biliary complications occurred in 87.5% of our patients.
Recurrent cholangitic episodes/flare-ups were documented in
FIGURE 3. Liver explant from a patient in our series, showing
advanced destruction of intrahepatic bile ducts.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.12/14 patients (no data were available for the remaining 2
patients). In 3/16 patients liver abscess formation was observed.
Severe cholangiosepsis was seen in 3/16 (19%) patients
(Table 3, Fig. 4).
Involvement of the gallbladder: Immediately following
cholestasis onset, one-half of our patients had sonographic
signs of acute (predominantly acalculous) cholecystitis.
Within the 1st year after initial injury acute cholecystitis
occurred in 69% (11/16) of the patients. Of these, 45%
(5/11) required emergency cholecystectomy. The cholecystitis
described was mostly an acalculous cholecystitis (10/11).
Gallbladder perforation evolved in 2 of these patients—in 1
patient 24 days after the onset of cholestasis. The perforation
rate was thus 18% (2/11).
Outcome, Progression, Listing, Need for
Transplantation
The data relating to outcome and transplantation are shown
in Tables 1 and 3 and Figure 5. After a short course of disease,
clinical signs and symptoms of liver cirrhosis appeared within a
few months. Most of the patients in our series (12/16) had to be
placed on the waiting list for liver transplant within 1 year after
the onset of cholestasis. The mean time to listing was 322 257
days (median: 225 days). The mean time from the onset of
cholestasis until transplantation was 35 months (median: 42
ry sclerosing cholangitis in critically ill patients.months). The earliest transplantation was performed 189 days
after the onset of cholestasis in a 63-year-old woman who
developed cholangiosepsis and multiple organ failure.
www.md-journal.com | 5
DISCUSSION
If ERC demonstrates PSC-like cholangiographic findings,
all types of sclerosing cholangiopathy must be considered in the
differential diagnosis. This includes secondary sclerosing chol-
angitis in critically ill patients (SSC-CIP). With mortality rates
of up to 50%, SSC-CIP represents a challenge to gastro-
enterologists and intensive care specialists.5 Currently, SSC-
CIP is still widely underdiagnosed. Early detection of the disease
and its complications is crucial to improving the poor prognosis.
In the initial stages of the disease, SSC-CIP must be
recognized as a cause of liver failure in ICU patients. In the
later stages, SSC-CIP must be differentiated from other types of
sclerosing cholangiopathy. This differentiation is necessary
with regard to the selection and timing of liver transplantation
as SSC-CIP progresses much more rapidly than other chol-
angiopathies. To enable clinical differentiation, characteristic
features of SSC-CIP must be identified.
As its name indicates critical illness is an obligatory
precondition for SSC-CIP.2–5 All of our patients had a history
of intensive care treatment for a life-threatening event.
Although this event often necessitates lengthy intensive care
treatment, long-term treatment (>7 days) is not required for the
destruction of the bile ducts, as previously believed. Rather, it
seems that bile duct damage is a very early event that manifests
within the first 5 to 7 days, as evidenced by the early increase of
cholestatic enzymes in our series.
There is a trend that the disease affects men more often
than women. In addition, SSC-CIP showed a predilection for
surgical patients, especially those in whom extensive tissue
destruction occurs, such as patients with polytrauma or those
undergoing major surgery. The first detectable sign of SSC-CIP
was an increase in the liver enzymes—as our data confirm.
SSC-CIP was characterized by a cholestatic pattern. In our
patients, GGT was the predominant enzyme, which increased
earlier and peaked more markedly than ALP. Hyperbilirubin-
emia occurred in the later stages. Although not specific, these
laboratory findings may be helpful in distinguishing SSC-CIP
from other causes of elevated liver enzymes in ICU patients, for
example, from septicaemia-associated cholestasis, in which a
hyperbilirubinemia predominates.6–8
Our data show that SSC-CIP is associated with markedly
elevated serum cholesterol. Elevated levels of cholesterol are
common in primary biliary cirrhosis (PBC), but occur less
frequently in PSC.9,10 In SSC-CIP, the combination of elevated
serum-cholesterol and pruritus may reflect disturbed bile
acid metabolism.
Unintentional weight loss appears to be a typical feature
of SSC-CIP and affected 94% of our patients. This contrasts
with reports of weight loss in only 35% to 40% of PSC
patients.11 Losing a mean 18 kg, our patients experienced a
level of weight loss otherwise seen only in wasting diseases.
The reason for this weight loss remains unclear. Conceivably,
it might have been associated with the liberation of cytokines
in the presence of chronic inflammation of the bile ducts.
This is a well-known mechanism in the case of cancer
cachexia. In cancer patients, inflammatory mediators such
as TNF-alpha can induce changes in lipid metabolism that
result in increased lipolysis, hyper-cholesterolemia, and a
reduction of total fat mass.12
Leonhardt et alDiagnosis
Cholangiography is mandatory for the diagnosis of SSC-
CIP. In clinical practice, the decision to perform endoscopic
6 | www.md-journal.comretrograde cholangiography (ERC) in ICU patients with chol-
estasis is often based on ultrasound findings of dilated bile
ducts. However, this approach delayed the diagnosis in our
series since only a few patients had dilated extrahepatic bile
ducts. Therefore, despite of the severe and striking initial course
of SSC-CIP, it took 3 months (mean) to establish the final
diagnosis. Typical ERC findings were biliary casts, destruction
of intrahepatic bile ducts, or finally the picture of a ‘‘pruned
tree.’’ These 3 different ERC findings occurred consecutively
and might reflect distinct stages in the development of the
disease. However, overlapping stages have also been observed.
Our findings show that SSC-CIP is mainly a disease of the
visible intrahepatic bile ducts—the extrahepatic bile ducts were
only marginally affected. Biliary cast formation may be con-
sidered pathognomonic for SSC-CIP, as suggested by the high
proportion of patients with biliary casts in our series. The casts
completely fill the bile ducts and may distend them. In all
patients initially presenting sonographically distended extrahe-
patic bile ducts, the first ERC’s revealed biliary casts. The
occurrence of biliary casts in association with either PSC or
IgG4 cholangiopathy has not been described in the literature.
After liver transplantation, the occurrence of biliary casts
is a known phenomenon, and an etiological association with
ischemic events is assumed.13,14 However, single cases of
‘‘biliary cast syndrome’’ in nontransplant patients have also
been described.15–18 This ‘‘biliary cast syndrome’’ in nontrans-
plant patients is presumably not a separate entity, but rather an
early stage of SSC-CIP, as supported by some case reports.19,20
In agreement with data from orthotopic liver transplantation we
found biliary casts in SSC-CIP only within the first year after
the initial event.13 Despite successful initial endoscopic
removal, 7 of our patients showed recurrence of the biliary
casts at subsequent ERC examinations.Whether these weremerely
the result of a sliding down of incompletely removed intrahepatic
fragments, or whether new casts were formed is not clear.
Complications of SSC-CIP
SSC-CIP carries a high risk for hepatobiliary compli-
cations. In 75% of our patients the clinical course was com-
plicated by acute acalculous cholecystitis, gallbladder
perforation, cholangitic liver abscess, or cholangiosepsis.
Involvement of the Gallbladder
It seems that the gallbladder epithelium is involved in the
pathogenetic process in SSC-CIP. This is underscored by the
high rate of acute cholecystitis (in the absence of a cholelithia-
sis) in the early stage of disease in our series. Acute acalculous
cholecystitis (AAC) is a serious and potentially fatal condition.
Ischemic necrosis of the gallbladder wall, often extending into
the deeper layers, causes a high spontaneous perforation rate, as
our data confirm. It is known that acute acalculous cholecystitis
shows a predilection to occur in critically ill patients after
trauma, burns, or major surgery.21–23 Because acute acalculous
cholecystitis has also been observed in association with Scho¨n-
lein–Henoch purpura, antiphospholipid syndrome and lupus
erythematosus, an ischemic pathogenesis for AAC is sup-
posed.24–26 A similar pathogenetic mechanism that could
explain the gallbladder involvement is hypothesized for SSC-
CIP. In ICU patients, an unexplained cholestasis and the
simultaneous appearance of acute acalculous cholecystitis
Medicine  Volume 94, Number 49, December 2015should raise the suspicion of SSC-CIP. Conversely, acute
acalculous cholecystitis is not a known phenomenon in patients
with PSC or IgG4-associated cholangiopathy.
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FIGURE 4. Cholangiography (via percutaneous biliary drainage)
Leonhardt et al Medicine  Volume 94, Number 49, December 2015Cholangitic Episodes/Cholangiosepsis/Liver
Abscesses
In our patients, the clinical course of disease was compli-
cated by recurrent episodes of bacterial cholangitis. In SSC-CIP,
these episodes may be secondary events explainable by the
presence of multifocal intrahepatic biliary strictures due to exten-
sive destruction of segmental and subsegmental bile ducts.
Furthermore, as a result of the duct damage peripheral bile duct
branches can lose their connection to the central ducts and become
‘‘excluded’’ bile ducts. The elimination of a biliary obstruction is
a prerequisite for successful antibiotic treatment of cholangitis.
Unfortunately in SSC-CIP this drainage is frequently inadequate
since peripheral, ‘‘excluded’’ ducts often can no longer be
reconnected by endoscopic means. The remaining obstruction
impairs the penetration of antibiotics into bile, limits the effec-
tiveness of the treatment, and increases the risk of cholangio-
sepsis. In the absence of drainage the mortality rate of cholangitis
is high, as is known from the pre-ERC era.27–30 This problem is
reflected by our data, showing a high rate of cholangiosepsis, and
among these patients a high fatality rate. Two of 3 patients died
from cholangiosepsis despite intensive therapeutic efforts while
still on the transplant waiting list. Furthermore, the stagnation of
bile flow also promotes cholangitic liver abscesses—almost 19%
of our patients developed this complication.
Progression/Need for Transplantation
Two aspects contributed to the short latency between the
onset of cholestasis and the need for transplantation observed in
our SSC-CIP cases. First, the clinical and histology data indicate
that the liver fibrosis progressed unusually quickly over a period
of a couple of months. This rapid and extensive fibrotic
response may be explainable by the large extent of initial
of a patient of our series with aburn injury, showing multiple
peribiliary liver abscesses. The patient died of unmanageable
cholangiosepsis while on the waiting list.cholangiocyte destruction of the intrahepatic bile ducts.31 Sec-
ond, on account of the risk of cholangiosepsis, transplantation is
urgently needed in cases with irreversible destruction of bile
8 | www.md-journal.comducts and recurrent severe cholangitis. Two patients of our
series died of cholangiosepsis while still on the transplant
waiting list; another patient with cholangiosepsis and multiple
organ failure had to be transplanted 195 days after the initial
event. Median liver transplantation-free survival was only 44
months (mean 40months) in our patients, compared to 89 to 112
months in other fibrosing cholangiopathies such as PSC, and 72
months in ‘‘classical’’ infective SSC.32–34 In view of the more
rapid disease progression, patients with SSC-CIP require closer
monitoring than patients with other forms of fibrosing chol-
angiopathy and an early cooperation with a transplantation
center should be initiated.35,36
Survival After Liver Transplantation
It was assumed earlier that patients with secondary scler-
osing cholangitis had a poor outcome after liver transplan-
tation.33,37 Our findings refute this. Eight of the 9
transplanted patients are alive and in a good state of health.
Only 1 female patient, who underwent simultaneous liver and
lung transplantation, died from pulmonary complications. The
resulting 1-year survival rate of 85% and 3-year survival rate of
83% correspond well with the survival rates for OLT in alco-
holic liver cirrhosis.
Study Limitations
The limitations of the present study are its retrospective
nature and the recruitment of the patients from a transplantation
center. Patients with an initially severe course who did not live
long enough to be listed, as also those with a milder course and
no liver transplantation, were not included in the study. Further
larger clinical studies can build on and consolidate our results.
Prospective studies with a control group, which makes it
possible to perform complex statistics generating P values
would be needed to validate our observations.
Frequency of SSC-CIP
The actual prevalence of SSC-CIP remains unknown and is
also not adequately reflected in our data (due to selection bias,
FIGURE 5. Transplant-free survival (Kaplan–Meier) of 16 cases
with SSC-CIP. SSC-CIP¼ secondary sclerosing cholangitis in criti-
cally ill patients.as mentioned above). Overall, 0.61% of all liver transplan-
tations performed at our center were due to SSC-CIP. Similar
rates have been observed, for example, in patients with
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
hemochromatosis (0.7% of all OLT at our center). For PSC the
figure was 6.2% in our center, indicating that SSC-CIP is 10
times rarer than PSC.
CONCLUSION
Despite some similarities with other sclerosing cholangio-
pathies, SSC-CIP shows characteristic features that allow for
discrimination of SSC-CIP from other entities. In particular,
the occurrence of biliary casts in patients with equivocal
findings of sclerosing cholangiopathy in ERC is suggestive
of SSC-CIP and excludes PSC and IgG4 cholangiopathies. Last
but not least, the fatal outcome of the complications of SSC-CIP
could be prevented by better recognition of the disease and its
natural history.
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